Huajing Wang

Title: Huajing Wang: Innovator in Antibody Development

Introduction

Huajing Wang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic use. With a total of 4 patents to his name, Wang is recognized for his innovative approaches to cancer treatment.

Latest Patents

One of Huajing Wang's latest patents is titled "ANTI-PD-L1 ANTIBODY AND USE THEREOF." This patent describes an antibody that binds to the PD-L1 protein or CD137 protein, along with an antigen-binding fragment or a variant thereof. Additionally, it includes a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. This bispecific antibody exhibits a strong ability to specifically recognize both proteins and can enhance T-cell activity. The patent also outlines the use of the antibody, antigen-binding fragment, or variant, as well as the bispecific antibody in the prevention and treatment of tumors.

Career Highlights

Huajing Wang is currently associated with Oricell Therapeutics Co., Ltd., where he continues to advance his research and development efforts. His work focuses on creating innovative solutions for cancer therapies, leveraging his expertise in antibody technology.

Collaborations

Wang collaborates with notable colleagues, including Xiaowen He and Bohua Li, who contribute to his research initiatives and help drive forward the mission of their organization.

Conclusion

Huajing Wang stands out as a key figure in the field of antibody development, with a focus on enhancing cancer treatment through innovative solutions. His contributions are paving the way for advancements in therapeutic applications.